Your watchdog for recalls, scams and product safety.

Health & Drug Alerts

Blood Pressure Drug Bottles Recalled Nationwide After Foreign Tablets or Capsules Found in Metoprolol Bottles Sold in Pharmacies

Bottle of metoprolol tablets with a recall warning for foreign tablets or capsules

WASHINGTON, DC — A New Jersey drugmaker has recalled 3,684 bottles of a prescription medication commonly used for high blood pressure and certain heart conditions after regulators said the product may contain other tablets or capsules.

The Food and Drug Administration said the reason for the action was the presence of foreign tablets or capsules. The agency did not identify what the other medication was or explain how it may have gotten into the bottles.

The recall affects bottles labeled with batch number 2611C065A1 and an expiration date of May 2028. The packaging lists National Drug Code 72888-210-00.

Advagen initiated the recall in late October and FDA classified it as Class II

Advagen voluntarily began the recall on Oct. 27, 2026, and first alerted recipients by letter. The FDA later classified the action as a Class II recall on Nov. 10, indicating the product could cause temporary or medically reversible health consequences, or the chance of serious health problems is remote.

The FDA notice did not say which pharmacies received the bottles or whether patients had already been exposed to them. It also did not list any reported adverse reactions tied to the recalled product.

No patient-specific instructions were included in the FDA entry, leaving customers and health care providers to look to the company or the dispensing pharmacy for next steps.

What metoprolol is used for and why the recall matters

The recalled medicine is metoprolol, a beta blocker that slows the heart rate and helps blood flow by relaxing blood vessels. Doctors prescribe it to treat high blood pressure, chest pain and heart failure, and to improve survival after a heart attack.

It is a management drug rather than a cure, so patients are generally told to keep taking it exactly as prescribed unless a clinician says otherwise. Changing the dose or schedule without medical advice can affect blood pressure and heart rhythm control.

Because the recall involves foreign tablets or capsules inside bottles of a commonly used prescription drug, the main concern is that patients may not be receiving only the medication shown on the label.

FDA guidance for patients taking metoprolol

Patients are advised not to increase, decrease or change how often they take metoprolol without guidance from a health professional. Anyone who misses a dose should skip it and return to the usual schedule rather than double up later.

Common side effects can include dizziness, tiredness, diarrhea, dry mouth, rash and itching. More serious symptoms such as breathing trouble, fainting, swelling, or a rapid, pounding or irregular heartbeat need immediate medical attention.

People who think they may have received the recalled bottles can check the batch number and National Drug Code on the packaging and contact their pharmacy or prescriber for advice.

No foreign tablet identity, strength or quantity was released

The FDA notice left several questions unanswered. It did not identify the foreign tablets or capsules, state their strength, or say how many may have been mixed into each bottle.

Regulators also did not say whether the foreign material posed a known safety risk on its own, or whether the problem was limited to packaging contamination. That means the exact level of risk for an individual patient cannot be determined from the notice alone.

Still, the presence of the wrong tablets or capsules in a prescription bottle is a quality-control concern that can confuse patients, complicate dosing and undermine confidence in the medication supply chain.

Patients can report side effects through the FDA MedWatch system

Anyone experiencing serious side effects from metoprolol or another regulated medicine can report the problem through the FDA’s MedWatch program. The system accepts reports from patients, consumers and health professionals.

MedWatch is designed to help the agency track possible problems involving prescription drugs and other medical products. Those reports can be used to identify patterns that may not be obvious from a single case.

For now, the recall centers on bottles already distributed under the listed batch number and product code. Consumers who have questions are typically advised to speak with a pharmacist or health care provider before making any changes to treatment.

Leave a Reply